An aberrant SALL4 activity has been reported in acute myeloid leukemia, lung adenocarcinoma, breast cancer, and other aggressive malignancies, and its overexpression is associated with poor prognosis and lower survival rate of patients [64–67]. Here, SALL4 is linked to lung adenocarcinoma.